• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Application
o Market segments
o Comparison by Application
o Gastrointestinal disorders – Market size and forecast 2019-2024
o Immunological conditions – Market size and forecast 2019-2024
o Others – Market size and forecast 2019-2024
o Market opportunity by application
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o APAC – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Bristol-Myers Squibb Co.
o Dow Inc.
o ENTEROME SA
o Ferring Pharmaceuticals AS
o Johnson & Johnson
o Kaleido Biosciences Inc.
o PureTech Health Plc
o Second Genome Therapeutics
o Seres Therapeutics Inc.
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2019 – 2024 ($ million)
• 13: Global market: Year-over-year growth 2019 – 2024 (%)
• 14: Five forces analysis 2019 & 2024
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2019
• 21: Application – Market share 2019-2024 (%)
• 22: Comparison by Application
• 23: Gastrointestinal disorders – Market size and forecast 2019-2024 ($ million)
• 24: Gastrointestinal disorders – Year-over-year growth 2019-2024 (%)
• 25: Immunological conditions – Market size and forecast 2019-2024 ($ million)
• 26: Immunological conditions – Year-over-year growth 2019-2024 (%)
• 27: Others – Market size and forecast 2019-2024 ($ million)
• 28: Others – Year-over-year growth 2019-2024 (%)
• 29: Market opportunity by Application
• 30: Customer landscape
• 31: Market share by geography 2019-2024 (%)
• 32: Geographic comparison
• 33: North America – Market size and forecast 2019-2024 ($ million)
• 34: North America – Year-over-year growth 2019-2024 (%)
• 35: Europe – Market size and forecast 2019-2024 ($ million)
• 36: Europe – Year-over-year growth 2019-2024 (%)
• 37: APAC – Market size and forecast 2019-2024 ($ million)
• 38: APAC – Year-over-year growth 2019-2024 (%)
• 39: ROW – Market size and forecast 2019-2024 ($ million)
• 40: ROW – Year-over-year growth 2019-2024 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: Impact of drivers and challenges
• 44: Vendor landscape
• 45: Landscape disruption
• 46: Industry risks
• 47: Vendors covered
• 48: Market positioning of vendors
• 49: Bristol-Myers Squibb Co. – Overview
• 50: Bristol-Myers Squibb Co. – Business segments
• 51: Bristol-Myers Squibb Co. – Key offerings
• 52: Bristol-Myers Squibb Co. – Key customers
• 53: Bristol-Myers Squibb Co. – Segment focus
• 54: Dow Inc. – Overview
• 55: Dow Inc. – Business segments
• 56: Dow Inc. – Key offerings
• 57: Dow Inc. – Key customers
• 58: Dow Inc. – Segment focus
• 59: ENTEROME SA – Overview
• 60: ENTEROME SA – Product and service
• 61: ENTEROME SA – Key offerings
• 62: ENTEROME SA – Key customers
• 63: ENTEROME SA – Segment focus
• 64: Ferring Pharmaceuticals AS – Overview
• 65: Ferring Pharmaceuticals AS – Product and service
• 66: Ferring Pharmaceuticals AS – Key offerings
• 67: Ferring Pharmaceuticals AS – Key customers
• 68: Ferring Pharmaceuticals AS – Segment focus
• 69: Johnson & Johnson – Overview
• 70: Johnson & Johnson – Business segments
• 71: Johnson & Johnson – Key offerings
• 72: Johnson & Johnson – Key customers
• 73: Johnson & Johnson – Segment focus
• 74: Kaleido Biosciences Inc. – Overview
• 75: Kaleido Biosciences Inc. – Product and service
• 76: Kaleido Biosciences Inc. – Key offerings
• 77: Kaleido Biosciences Inc. – Key customers
• 78: Kaleido Biosciences Inc. – Segment focus
• 79: PureTech Health Plc – Overview
• 80: PureTech Health Plc – Business segments
• 81: PureTech Health Plc – Key offerings
• 82: PureTech Health Plc – Key customers
• 83: PureTech Health Plc – Segment focus
• 84: Second Genome Therapeutics – Overview
• 85: Second Genome Therapeutics – Product and service
• 86: Second Genome Therapeutics – Key offerings
• 87: Second Genome Therapeutics – Key customers
• 88: Second Genome Therapeutics – Segment focus
• 89: Seres Therapeutics Inc. – Overview
• 90: Seres Therapeutics Inc. – Product and service
• 91: Seres Therapeutics Inc. – Key offerings
• 92: Seres Therapeutics Inc. – Key customers
• 93: Seres Therapeutics Inc. – Segment focus
• 94: Takeda Pharmaceutical Co. Ltd. – Overview
• 95: Takeda Pharmaceutical Co. Ltd. – Product and service
• 96: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 97: Takeda Pharmaceutical Co. Ltd. – Key customers
• 98: Takeda Pharmaceutical Co. Ltd. – Segment focus
• 99: Currency conversion rates for US$
• 100: Research Methodology
• 101: Validation techniques employed for market sizing
• 102: Information sources
• 103: List of abbreviations
【掲載企業】
Bristol-Myers Squibb Co., Dow Inc., ENTEROME SA, Ferring Pharmaceuticals AS, Johnson & Johnson, Kaleido Biosciences Inc., PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Takeda Pharmaceutical Co. Ltd.
【免責事項】
https://www.marketreport.jp/reports-disclaimer